Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban

Exclusion Criteria

• •Patients with a plan less than 6 months of anticoagulation for most recent DVT or PE
• •Patients with allergic reaction to Apixaban
• •Patients with active bleeding or high risk for bleeding contraindicating treatment with LMWH
• •Patients with planned surgery in the next 2 weeks
• •Patients previously treated with Apixaban
• •Patients requiring Acetylsalicylic Acid (ASA) greater than165 mg/day at enrollment
• •Patients requiring dual anti-platelet therapy (ASA plus clopidogrel or ASA plus ticlopidine) at enrollment.
• •Subjects with transition for dual anti-platelet therapy or monotherapy prior to enrollment will be eligible for the study
• •Patients who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness
• •Any condition, which in the opinion of the investigator, would put the subject at an unacceptable risk from participating in the study
• •Any other medical, social, logistical, or psychological reason, which in the opinion of the investigator, would preclude compliance with, or successful completion of, the study protocol
• •Known active and clinically significant liver disease (e.g., hepatorenal syndrome)
• •Known bacterial endocarditis
• •Know uncontrolled hypertension: systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg; (subjects who have a transient, higher blood pressure elevation associated with acute PE \[upper limit: systolic blood pressure 200 mm Hg or diastolic blood pressure 100 mm Hg\] may enter the study;) elevated blood pressure that is persistent 1 - 2 days after the index DVT or PE should be treated according to local guidelines